Yervoy

Biotech

Jounce gets trounced as phase 2 data disappoint once again

Jounce is reevaluating a top monoclonal antibody program after it failed to adequately reduce tumor size in combination with another lead asset.
Max Bayer Aug 31, 2022 7:30am

BMS melanoma, genitourinary commercial lead heads to miR

Aug 13, 2021 9:45am

BMS' LAG-3 drug boosts Opdivo in staving off melanoma

May 19, 2021 5:00pm

Idera's TLR9 drug flunks melanoma phase 3, tanking stock

Mar 19, 2021 8:45am

Xilio raises $95M to take twists on Yervoy and IL-2 into clinic 

Feb 24, 2021 8:00am

Jounce sinks as it ditches phase 2 Yervoy combo trial

Nov 3, 2020 9:55am